Precigen, Inc.

NasdaqGS:PGEN Stock Report

Market Cap: US$2.0b

Precigen Management

Management criteria checks 4/4

Precigen's CEO is Helen Sabzevari, appointed in Jan 2020, has a tenure of 6.5 years. total yearly compensation is $5.35M, comprised of 18.7% salary and 81.3% bonuses, including company stock and options. directly owns 1.06% of the company’s shares, worth $20.95M. The average tenure of the management team and the board of directors is 6.5 years and 12.3 years respectively.

Key information

Helen Sabzevari

Chief executive officer

US$5.4m

Total compensation

CEO salary percentage18.68%
CEO tenure6.5yrs
CEO ownership1.1%
Management average tenure6.5yrs
Board average tenure12.3yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 26

Precigen: Entering The Oncology 'Sweet Spot'

Summary Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call. Risks include competitive threats from INO-3107, but PGEN's commercial momentum remains strong. Read the full article on Seeking Alpha
Narrative Update • Jun 26

PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside

Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.
Analysis Article • Jun 21

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...
Seeking Alpha • Feb 28

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking Alpha
Seeking Alpha • Feb 10

Precigen: Successful Proof Of Platform, But Cash Worries Remain

Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking Alpha
Analysis Article • Feb 28

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 20

Precigen: RRP Targeting With AdenoVerse Technology Platform

Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. PRGN-2009 which also uses the AdenoVerse technology has one phase 2 study targeting OPSCC underway and another one targeting recurrent/metastatic cervical cancer patients expected to begin in 2024. Read the full article on Seeking Alpha
Analysis Article • Nov 04

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Helen Sabzevari's remuneration changed compared to Precigen's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$383m

Dec 31 2025US$5mUS$1m

-US$430m

Sep 30 2025n/an/a

-US$426m

Jun 30 2025n/an/a

-US$124m

Mar 31 2025n/an/a

-US$157m

Dec 31 2024US$5mUS$1m

-US$126m

Sep 30 2024n/an/a

-US$140m

Jun 30 2024n/an/a

-US$135m

Mar 31 2024n/an/a

-US$97m

Dec 31 2023US$4mUS$1m

-US$96m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$79m

Dec 31 2022US$3mUS$1m

-US$80m

Sep 30 2022n/an/a

-US$84m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$108m

Dec 31 2021US$3mUS$1m

-US$111m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020US$20mUS$1m

-US$104m

Sep 30 2020n/an/a

-US$100m

Jun 30 2020n/an/a

-US$122m

Mar 31 2020n/an/a

-US$138m

Dec 31 2019US$1mUS$500k

-US$169m

Compensation vs Market: Helen's total compensation ($USD5.35M) is about average for companies of similar size in the US market ($USD5.20M).

Compensation vs Earnings: Helen's compensation has been consistent with company performance over the past year.

CEO

Helen Sabzevari (64 yo)

6.5yrs
Tenure
US$5,354,329
Compensation

Dr. Helen Sabzevari, Ph.D. MPH, served as Independent Director at Kinnate Biopharma Inc. from June 2021 to April 3, 2024. She has been President and Chief Executive Officer of Precigen, Inc (formerly Intre...

Leadership Team

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman18.4yrsUS$600.00k3.76%
$ 74.5m
Helen Sabzevari
President6.5yrsUS$5.35m1.06%
$ 21.0m
Harry Thomasian
Chief Financial Officer4.8yrsUS$1.49m0.099%
$ 2.0m
Rutul Shah
Chief Operating Officer6.4yrsUS$1.56m0.14%
$ 2.8m
Donald Lehr
Chief Legal Officer & Corporate Secretary15.5yrsUS$1.43m0.21%
$ 4.2m
Phil Tennant
Chief Commercial Officer2yrsUS$1.23m0.039%
$ 774.8k
Steven Harasym
VP & Head of Investor Relations8.5yrsno datano data
Douglas Brough
Senior VP & Head of Researchno datano datano data
Bryan Butman
Senior VP & Head of CMCno datano datano data
Amy Lankford
Senior VP & Head of Clinical Operations and Regulatory Affairs3.1yrsno datano data
David Witte
Chief Executive Officer of MBP Titan LLC7.5yrsno datano data
6.5yrs
Average Tenure
64yo
Average Age

Experienced Management: PGEN's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Randal Kirk
Executive Chairman18.4yrsUS$600.00k3.76%
$ 74.5m
Helen Sabzevari
President6.1yrsUS$5.35m1.06%
$ 21.0m
Jeffrey Kindler
Independent Director14.7yrsUS$319.00k0.057%
$ 1.1m
Fred Hassan
Independent Director10.1yrsUS$313.00k0.35%
$ 6.9m
Cesar Alvarez
Independent Director18.4yrsUS$312.50k0.22%
$ 4.4m
James Turley
Lead Independent Director12.3yrsUS$312.50k0.19%
$ 3.8m
Steve Frank
Independent Director18.4yrsUS$300.00k0.34%
$ 6.8m
Nancy Agee
Independent Director2yrsUS$306.50k0.086%
$ 1.7m
Vinita Gupta
Independent Director9.3yrsUS$313.00k0.19%
$ 3.7m
12.3yrs
Average Tenure
71yo
Average Age

Experienced Board: PGEN's board of directors are seasoned and experienced ( 12.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 10:13
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Precigen, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
Derik de BruinBofA Global Research
Justin WalshB. Riley Securities, Inc.